| OMEROS CORP. DL -,01 |
| USA |
| Gesundheit |
| US6821431029 / A0NBFF |
| 3O8 (Frankfurt) / OMER (NASDAQ) |
| FRA:3O8, ETR:3O8, 3O8:GR, NASDAQ:OMER |
| - |
| https://www.omeros.com/ |
|
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in are..
>Volltext.. |
| 853.11 Mio. EUR |
| 1004.67 Mio. EUR |
| 8.56 Mio. EUR |
| -90.3 Mio. EUR |
| 74.58 Mio. EUR |
| 0.95 EUR |
| 268.83 Mio. EUR |
| 1.65 Mio. EUR |
| -87.53 Mio. EUR |
| 2.28 |
| - |
| - |
| - |
| - |
| - |
| - |
| OMEROS |
| 13.08.26 |